Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials
Authors
Brian Angus (ORCID: https://orcid.org/0000-0003-3598-7784)
Department of Foreign Affairs and Trade, Australian Government
Bundesministerium für Bildung und Forschung
Medical Research Council
European and Developing Countries Clinical Trials Partnership
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article
Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials
Brian Angus, Greg Glenn, Louis Fries, Alphonse Ouédraogo et al.
Citations
10 citations
Journal
The Lancet Microbe
Topics
Malaria Research and Control
Field-Weighted Citation Impact (FWCI)
18.79
article
Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials
Brian Angus, Greg Glenn, Louis Fries, Alphonse Ouédraogo, Alfred B. Tiono, Eleanor Berrie, Sam Coulibaly, Daniel Silman, Jenny M. Reimer, Nicola Green, Duncan Bellamy, Florian Brod, D. J. Lewis, Katie Ewer, Sodiomon B. Sirima, Lisa Stockdale, Issa Nébié, Ian Poulton, Richard Morter, Egeruan B. Imoukhuede, Daniel Wright, Sarah C. Gilbert, Carly M. Bliss, Pedro M. Folegatti, Edith C. Bougouma, Sophie Jamieson, Navin Venkatraman, Sarah Moyle, Jonathan Powlson, Katharine A. Collins, Ekta Mukhopadhyay, E. M. Dickinson, Georgina Bowyer, Rachel Roberts, Mehreen S Datoo, Karin Lövgren‐Bengtsson, Nicola K. Viebig, Amidou Diarra, Alison Lawrie, Adrian V S Hill, Megan Baker
article en
10 citations
Abstract
No abstract available for this paper.
Publication Tag
The Lancet MicrobeVol. 6(3)
Institutions
Heidelberg University (DE), Churchill Hospital (GB), Hammersmith Hospital (GB), University Hospital Heidelberg (DE), John Radcliffe Hospital (GB), University of Oxford (GB), Novavax (United States) (US), Vienna Vaccine Safety Initiative (DE), Centre National de Recherche et de Formation sur le Paludisme (BF), Oxford BioMedica (United Kingdom) (GB), Jenner Institute (GB), Novavax (Sweden) (SE), Groupe de Recherche et d’Action sur le Foncier (BF)
Funders
Irish Aid, Wellcome Trust, National Institute for Health and Care Research, European Commission, Department of Foreign Affairs and Trade, Australian Government, Bundesministerium für Bildung und Forschung, Medical Research Council, European and Developing Countries Clinical Trials Partnership